AzTrials
AzTrials

Segmental Lung AtelectasisNCT07442708

Segmental Lung Recruitment: a Randomized Controlled Trial

A study testing Segmental lung recruitment and Conventional lung recruitment in people with Segmental Lung Atelectasis, run by Clinical Hospital Center Rijeka.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study compares two ways of reopening collapsed parts of the lung in patients on a ventilator. In one group, doctors use a small camera (bronchoscope) to guide air pressure directly to the blocked part of the lung. In the other group, increased air pressure is applied to the whole lung using the ventilator. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Segmental Lung Atelectasis
What is being tested?
Segmental lung recruitment and Conventional lung recruitment
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
No sites listed yet
Study dates
25 Feb 2026to 15 Apr 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • treatment in ICU, presence of radiologically or clinically confirmed pulmonary atelectasis during ICU treatment, requirement for mechanical ventilation

Who cannot join

  • primary or secondary lung malignancy

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

About this study

This study compares two ways of reopening collapsed parts of the lung in patients on a ventilator.

In one group, doctors use a small camera (bronchoscope) to guide air pressure directly to the blocked part of the lung. In the other group, increased air pressure is applied to the whole lung using the ventilator.

Patients are carefully monitored to ensure safety.

Read the detailed description

This study will compare two lung recruitment strategies in mechanically ventilated patients with segmental atelectasis.

In the experimental group, patients will undergo bronchoscopy-guided targeted segmental recruitment using endobronchial bloker. A flexible bronchoscope will be introduced through the endotracheal tube and advanced under direct visualization to the affected lung segment. The endobronchial blocker will be positioned to temporarily block the segmental bronchus, creating a closed system. Sustained positive pressure of 30 cmH₂O will be applied directly to the atelectatic segment for 30 minutes, while standard ventilator settings will be maintained for the remainder of the lung. Continuous monitoring of oxygen saturation, heart rate, blood pressure, and end-tidal carbon dioxide will be maintained. The maneuver will be immediately discontinued if oxygen saturation decreases by more than 10%, systolic blood pressure decreases by more than 20%, or heart rate changes by more than 20% from baseline values.

In the control group, patients will receive a conventional whole-lung recruitment maneuver. Continuous positive airway pressure (CPAP) of 40 cmH₂O will be applied to the entire respiratory system for 40 seconds using the ventilator. Monitoring and safety criteria will be identical to those used in the experimental group, and the maneuver will be discontinued if predefined thresholds are exceeded.

All patients will receive lung-protective mechanical ventilation according to current guidelines. Tidal volumes will be maintained at 6-8 mL/kg predicted body weight, plateau pressures will be limited to less than 30 cmH₂O, and positive end-expiratory pressure (PEEP) will be adjusted according to FiO₂-PEEP tables. Permissive hypercapnia will be accepted provided arterial pH remains above 7.20.

The primary outcomes will focus on safety and will include the incidence of clinically significant desaturation (oxygen saturation decrease greater than 5% from baseline) and hemodynamic instability (systolic blood pressure decrease greater than 20 mmHg or need for vasopressor dose escalation) during and within 30 minutes after the maneuver.

Secondary outcomes will include changes in respiratory parameters measured at baseline, 24 hours, and 48 hours after the intervention. These parameters will include the PaO₂/FiO₂ ratio, static respiratory system compliance, driving pressure, plateau pressure, and PEEP. Arterial blood gas analysis will be performed at baseline, 1 hour, 24 hours, and 48 hours to assess pH, PaO₂, PaCO₂, bicarbonate, and base excess.

Clinical outcomes will include duration of mechanical ventilation following the maneuver, length of stay in the intensive care unit, duration of ward treatment after ICU discharge, in-hospital mortality, and 28-day all-cause mortality.

All patients will undergo contrast-enhanced chest computed tomography. Lung parenchyma will be segmented using 3D Slicer software to quantify total lung volume and non-ventilated (pathologic) lung regions. The proportion of non-ventilated lung tissue relative to total lung volume will be calculated. A change greater than 15% in the proportion of non-ventilated lung between baseline and follow-up scans will be considered clinically significant.

Venous blood samples will be collected at baseline, 24 hours, and 48 hours. Serum concentrations of interleukin-2 and interleukin-8 will be measured using ELISA assays. Samples will be analyzed in duplicate, and assay variability will be less than 10%.

Being tested
Segmental lung recruitment, Conventional lung recruitment
Keywords
: Lung atelectasis; Segmental lung recruitment; Mechanical ventilation; Intensive care unit; Recruitment maneuvers

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Segmental lung recruitmentProcedure or surgery

    Patients will undergo bronchoscopy-guided targeted segmental lung recruitment via endobronchial blocker. Flexible bronchoscope will be introduced through the endotracheal tube and advanced under direct visualization to the affected lung segment. The endobronchial blocker will be positioned to temporarily occlude the segmental bronchus, creating a closed system. Sustained positive pressure of 30 cmH₂O will be applied directly to the atelectatic segment for 30 minutes, while standard ventilator settings will be maintained for the remaining lung tissue.

  • Conventional lung recruitmentProcedure or surgery

    Patients in the control group received standard recruitment maneuvers consisting of continuous positive airway pressure (CPAP) of 40 cmH₂O applied to the entire respiratory system for 40 seconds. This approach represents the conventional recruitment strategy used in clinical practice.

Study groups in NCT07442708
Study groupRoleWhat they receive
Segmental lung recruitmentExperimentalPatients will undergo bronchoscopy-guided targeted segmental lung recruitment via endobronchial blocker. Flexible bronchoscope will be introduced through the endotracheal tube and advanced under direct visualization to the affected lung segment. The endobronchial blocker will be positioned to temporarily occlude the segmental bronchus, creating a closed system. Sustained positive pressure of 30 cmH₂O will be applied directly to the atelectatic segment for 30 minutes, while standard ventilator settings will be maintained for the remaining lung tissue.
Receives: Procedure: Segmental lung recruitment
Control groupActive comparatorPatients in the control group will receive standard recruitment maneuvers using continuous positive airway pressure applied for a short, sustained period at a level consistent with conventional clinical practice. This approach will reflect the commonly used recruitment strategy in routine care.
Receives: Procedure: Conventional lung recruitment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety profile

    The primary safety outcomes will be the incidence of clinically significant desaturation and hemodynamic instability during and within 30 minutes following the recruitment.

    Measured: From enrollment 72 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Mar 2026
  2. Study start25 Feb 2026 (estimated)
  3. Primary completion25 Mar 2026 (estimated)
  4. Study completion15 Apr 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07442708
Sponsor's protocol ID
SEGREC2026
Status last verified
Feb 2026
First submitted
24 Feb 2026
Last updated
2 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Protic A, Bura M, Juricic K. A 23-year-old man with left lung atelectasis treated with a targeted segmental recruitment maneuver: a case report. J Med Case Rep. 2020 Jun 24;14(1):77. doi: 10.1186/s13256-020-02409-6.

    PubMed 32576293
  • Protic A, Bura M, Sustic A, Brusic J, Sotosek V. Segmental Lung Recruitment in Patients with Bilateral COVID-19 Pneumonia Complicated by Acute Respiratory Distress Syndrome: A Case Report. Medicina (Kaunas). 2023 Jan 11;59(1):142. doi: 10.3390/medicina59010142.

    PubMed 36676766

Questions about this trial

What is this clinical trial studying?

A study testing Segmental lung recruitment and Conventional lung recruitment in people with Segmental Lung Atelectasis, run by Clinical Hospital Center Rijeka.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Matej Bura, MD (00385917387967, matej.bura@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety profile (time frame: From enrollment 72 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07442708, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in